AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Cancer-Related Hair Loss and Acne Management in Oncology Patients

Description

The talk reviewed management of hair loss and acne in oncology patients, focusing first on chemotherapy-induced alopecia, which results from cytotoxic damage to rapidly dividing hair matrix cells. Scalp cooling was presented as an effective preventive strategy that reduces scalp blood flow, follicular uptake of chemotherapy, and follicular metabolism, with contraindications in hematologic, CNS, and head/neck cancers and in patients with cold-sensitive disorders. Minoxidil was discussed as useful mainly after hair loss occurs rather than for prevention, and endocrine therapy–induced alopecia in patients taking tamoxifen or aromatase inhibitors was noted to resemble androgenetic alopecia. Low-dose oral minoxidil appears not to increase cancer risk and may be effective, though caution is advised in patients with possible chemotherapy-related cardiomyopathy. Spironolactone and finasteride were reviewed with attention to theoretical hormone-sensitive cancer concerns; overall evidence was somewhat reassuring for new cancer risk, but the speaker recommended caution and shared decision-making for patients with a history of hormone receptor–positive breast or gynecologic cancer. Topical formulations may have less systemic absorption. Hair supplements, especially those containing biotin, can interfere with important oncologic lab tests. For treatment-related hair loss, the speaker favored minoxidil first, then dose escalation or compounded therapies, PRP, or low-level light therapy, with PRP contraindicated in hematologic malignancy, active scalp malignancy, and thrombocytopenia. For acne, long-term antibiotic exposure was mentioned as a possible cancer-associated risk, supporting antibiotic stewardship, while isotretinoin was described as not increasing malignancy risk and even studied as an anti-cancer adjunct in some settings. Finally, acneiform eruptions from targeted therapies should be managed differently from typical acne, starting with topical antibiotics and steroids, then oral antibiotics, while avoiding harsh agents like retinoids and benzoyl peroxide; isotretinoin can be used if needed.

View more

Conclusions

  • Scalp cooling is an effective way to reduce chemotherapy-induced alopecia, but it should be avoided in certain malignancies and cold-sensitive conditions.
  • Topical minoxidil does not prevent chemotherapy-induced hair loss, but starting it after hair loss can speed regrowth.
  • Endocrine therapy-induced alopecia behaves similarly to androgenetic alopecia, so treatments used for pattern hair loss are often appropriate.
  • Low-dose oral minoxidil appears safe in cancer patients overall and can improve multiple types of hair loss, though cardiac history must be considered.
  • Spironolactone does not appear to increase the risk of new breast or gynecologic cancers in the better-matched dermatology population, but caution remains warranted in patients with prior hormone-sensitive cancer.
  • Evidence for spironolactone and breast cancer recurrence is mixed and limited by older, non-dermatology populations, so shared decision-making with oncology is recommended.
  • Finasteride has reassuring safety data in men, but limited female data and possible estrogen changes make it a cautious choice in patients with hormone-sensitive cancer histories.
  • Topical spironolactone and topical finasteride likely have low systemic absorption and may be safer options than oral forms.
  • Hair-loss supplements, especially those containing biotin, can interfere with important cancer-related lab tests and should be used cautiously.
  • For cancer patients with hormonal or endocrine-related hair loss, a stepwise approach starting with minoxidil and escalating to compounded topicals, PRP, or low-level light therapy is reasonable.
  • Long-term antibiotic exposure may be associated with a small increased cancer risk, supporting antibiotic stewardship when treating acne in cancer patients.
  • Isotretinoin does not appear to increase malignancy risk and remains a safe acne treatment in cancer populations.
  • Acneiform eruptions from targeted cancer therapies are managed differently from acne vulgaris, often with topical steroids and antibiotics while avoiding harsh acne products.
  • Overall, routine dermatologic treatments can often be used safely in patients with cancer, but medication choice should be tailored to cancer type, treatment history, and recurrence risk.
  • Rugo HS et al. JAMA. 2017. Machine scalp cooling protected against hair loss in 66% of 124 women with breast cancer, compared with 0% in the uncooled group.
  • Nangia J et al. JAMA. 2017. SCALP randomized multisite placebo-controlled trial; successful hair preservation in 50.5% of women who received scalp cooling.
  • Freites-Martinez A et al. Endocrine Therapy-Induced Alopecia in Patients With Breast Cancer. JAMA Dermatol. 2018 Jun 1;154(6):670-675.#10.1001/jamadermatol.2018.0454
  • Biggar and colleagues. Cancer Epidemiology. 2013.
  • Bommareddy and colleagues. JAMA Dermatology. 2022.
  • Hill RC, Wang Y, Shaikh B, Lipner SR. No increased risk of breast or gynecologic malignancies in women exposed to spironolactone for dermatologic conditions: A retrospective cohort study. J Am Acad Dermatol. 2024 Feb 27:S0190-9622(24)00418-3.#10.1016/j.jaad.2024.02.030
  • Wei C, Bovonratwet P, Gu A, Moawad G, Silverberg JI, Friedman AJ. Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. J Am Acad Dermatol. 2020 Oct;83(4):1021-1027.#10.1016/j.jaad.2020.05.081
  • Mager L, Ueltschi O, Rose L, Dulmage B. Biotin Supplements for Hair and Nail Regrowth: A Caution for Oncologists. JCO Oncol Pract. 2025 Sep 15:OP2500693. doi: 10.1200/OP-25-0693. Epub ahead of print. PMID: 40953333.#10.1200/OP-25-0693
  • Petrelli F, Ghidini M, Ghidini A, Perego G, Cabiddu M, Khakoo S, Ogioni E, Abeni C, Hahne JC, Tomasello G, Zaniboni A. Use of Antibiotics and Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies. Cancers (Basel). 2019 Aug 14;11(8):1174.#10.3390/cancers11081174
  • Sarkar P, Sultana N, Debnath PK, Rouf R, Mubarak MS, Uddin SJ, Popa D, Calina D, Sharifi-Rad J. Isotretinoin as a Multifunctional Anticancer Agent: Molecular Mechanisms, Pharmacological Insights and Therapeutic Potential. Archiv der Pharmazie. 2025;358:e70084.#10.1002/ardp.70084